<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693937</url>
  </required_header>
  <id_info>
    <org_study_id>SRTS-SRT-001</org_study_id>
    <nct_id>NCT03693937</nct_id>
  </id_info>
  <brief_title>A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)</brief_title>
  <official_title>A Retrospective Registry Study to Evaluate the Long-Term Efficacy and Safety of Superficial Radiation Therapy (SRT) in Individuals With Non-Melanoma Skin Cancer (NMSC) .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sensus Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sensus Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-Melanoma Skin Cancer (NMSC) is the most commonly occurring type of skin cancer, and
      predominantly comprises (98%) Basal Cell Carcinomas (BCC) and Squamous Cell Carcinomas (SCC).
      About 3.3 million people in the United States (U.S.) are diagnosed with NMSC annually,
      equating about 5.4 million BCCs and SCCs. Low-dose Superficial Radiation Therapy (SRT)
      effectively destroys BCC and SCC without any invasive cutting, bleeding or stitching. There
      is no need for anesthesia, no risk of infection or scarring and no need for reconstructive
      plastic surgery. Healing time is quick with minimal to no post-treatment downtime or
      lifestyle restrictions. It is therefore both a viable and highly desirable alternative to
      invasive, painful and higher-risk surgical procedures. This study will utilize retrospective
      chart analysis to evaluate the outcomes of SRT-100™ therapy on NMSC lesions over a long-term
      post-treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-Melanoma Skin Cancer (NMSC) is the most commonly occurring type of skin cancer and
      accounts for about one-third of all cancers. NMSCs predominantly (98%) include Basal Cell
      Carcinomas (BCC) and Squamous Cell Carcinomas (SCC). Basal cell carcinomas (BCC) are
      abnormal, uncontrolled growths or lesions that arise in the skin's basal cells that line the
      deepest layer of the epidermis, occurring most commonly on sun-exposed areas of the face,
      head and neck. They are slow-growing cancers that rarely metastasize. Delayed or ineffective
      treatment of BCCs can lead to disfigurement of the lesion and recurrence. Squamous cell
      carcinomas (SCC) are uncontrolled growths of abnormal cells arising from the squamous cells
      in the epidermis producing keratin, also typically developing on sun-exposed and damaged body
      areas such as the face, ears, neck, lips, back of the hands, arms and legs. SCCs may be slow
      or rapidly growing with significant tenderness and pain and may become disfiguring and fatal
      if left untreated and allowed to grow.

      About 3.3 million people in the United States (U.S.) are diagnosed with NMSC annually,
      equating about 5.4 million BCCs and SCCs. Diagnosis and treatment of NMSC in the U.S.
      increased by 77% between 1994 and 2014. The incidence of BCC is about 4 times that of SCC. An
      estimated 4.3 million cases of BCC are diagnosed annually in the U.S. resulting in over 3,000
      deaths. Over 1 million cases of SCC are diagnosed in the U.S. annually, resulting in over
      15,000 deaths. SCC has a 4% annual incidence of metastasis. About 90% of NMSC is associated
      with repeated and unprotected skin exposure to ultraviolet (UV) rays

      Treatment options for NMSC include surgery, cryotherapy, curettage and electrodesiccation,
      radiation therapy including superficial radiation therapy (SRT), photodynamic therapy,
      various forms of brachytherapy, and chemotherapeutic agents.

      Low-dose SRT effectively destroys BCC and SCC without any invasive cutting, bleeding or
      stitching. There is no need for anesthesia, no risk of infection or scarring and no need for
      reconstructive plastic surgery. Healing time is quick with minimal to no post-treatment
      downtime or lifestyle restrictions. It is therefore both a viable and highly desirable
      alternative to invasive, painful and higher-risk surgical procedures. This study will utilize
      retrospective chart analysis to evaluate the outcomes of SRT-100™ therapy on NMSC lesions
      over a long-term post-treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Actual">March 16, 2019</completion_date>
  <primary_completion_date type="Actual">March 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cure Rate</measure>
    <time_frame>5 years</time_frame>
    <description>NMSC cure rate will be calculated as the percentage of lesions that attained complete cure following SRT-100 treatment completion.</description>
  </primary_outcome>
  <enrollment type="Actual">776</enrollment>
  <condition>Non-melanoma Skin Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SRT-100</intervention_name>
    <description>The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population comprises patients who were treated with the SRT-100™ for one or more
        non-melanoma skin cancers (NMSCs) and have follow-up data.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with SRT-100™.

          -  Treatment date of December 31, 2015 or earlier.

          -  Non-Melanoma Skin Cancer (NMSC) pathological diagnosis of confirmed squamous cell
             carcinoma (SCC) or basal cell carcinoma (BCC).

          -  Histopathological Grade: G1 (well differentiated); G2 (moderately differentiated) or
             Gx (not assessed).

          -  One lesion is treated, or more than one lesion is treated with a minimum of a 5 mm gap
             between the edges of the lesion margins.

          -  Required retrospective data is existing and sufficient.

        Exclusion Criteria:

          -  Lesions of etiology other than non-melanoma skin cancer (NMSC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>William Roth, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology and Dermatological Surgery</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 1, 2018</study_first_submitted>
  <study_first_submitted_qc>October 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03693937/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-Melanoma Skin Cancers (NMSCs)</title>
          <description>Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="776"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="776"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Melanoma Skin Cancers (NMSCs)</title>
          <description>Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.94" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Participant Race</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure Rate</title>
        <description>NMSC cure rate will be calculated as the percentage of lesions that attained complete cure following SRT-100 treatment completion.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Melanoma Skin Cancers (NMSCs)</title>
            <description>Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Cure Rate</title>
          <description>NMSC cure rate will be calculated as the percentage of lesions that attained complete cure following SRT-100 treatment completion.</description>
          <units>lesions</units>
          <param>Number</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="776"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Non-Melanoma Skin Cancers (NMSCs)</title>
          <description>Non-Melanoma Skin Cancers (NMSCs) treated with SRT-100 therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="776"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="776"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Radiation Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="776"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Isabelle Raymond</name_or_title>
      <organization>Sensus Healthcare</organization>
      <phone>561-922-5808</phone>
      <email>iraymond@sensushealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

